A new report from industry analyst IQVIA Institute for Human Data Scienc has found that opioid prescriptions in the USA have declined 17% in the last year, the largest annual drop ever.
The researchers found that while the volume of opioid prescriptions increased every year since 1992, a series of regulatory and legislative measures enacted in 2011 caused a 4% year-on-year decline, followed by a 12% decline in 2017 and a 17% drop in 2018.
In recent years, the USA has been in the grip of an opioid crisis, with pharmaceutical marketing practices blamed for widespread overprescribing and subsequent opioid misuse.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze